Revisions of international consensus Fukuoka guidelines
for the management of IPMN of the pancreas
Abstract
1 Introduction
2 Classification
2-1 Criteria for distinction of BD-IPMN and main duct IPMN(MD-IPMN)
2-2 Definition of malignant IPMN
3 Investigation
3-1 Work-up for cystic lesions of the pancreas
3-2 Distinction of BD-IPMN from other pancreatic cysts
3-3 Roles of cyst fluid analysis and cytology obtained by EUS-FNA
in the diagnosis of cystic lesions of the pancreas
3-4 Role of cytology and/or analysis of the pancreatic juice
in the diagnosis of invasive carcinoma and HGD in BD-IPMN
3-5 Distinction of BD-IPMN from serous cystic neoplasm(SCN)
4 Indications for resection
4-1 Indications for resection of BD-IPMN
4-2 Indications for resection of MD-IPMN
5 Methods of resection and other treatments
5-1 Methods of pancreatectomy for invasive and non-invasive IPMNs
5-2 Role of mucosal ablation by ethanol injection under EUS guidance
in the management of IPMN
5-3 Approach to multifocal BD-IPMN
6 Histological aspects
6-1 Types of invasive carcinoma of IPMN
6-2 Pathologic definition of minimally invasive carcinoma
derived from IPMN
6-3 Distinction and clinical relevance of gastric, intestinal,
pancreatobiliary, and oncocytic forms of IPMNs
6-4 Role of intraoperative frozen section evaluation in the surgical
management of IPMNs
6-5 Distinction of carcinoma derived from and concomitant with an IPMN
7 Methods of follow-up
7-1 Follow-up of non-resected IPMN
7-2 Follow-up of surgically resected IPMN
7-3 Possible occurrence of PDAC in patients with IPMN on follow-up:
impact of family history of PDAC
7-4 Possible occurrence of malignant neoplasms in other organs
in patients with IPMN on follow-up